menu
    • menu
    [{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Orcosa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NYU Langone Health \/ NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ NYU Langone Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ NYU Langone Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"NIDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Psilocybine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NYU Langone Health","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NYU Langone Health \/ NIDA","highestDevelopmentStatusID":"14","companyTruncated":"NYU Langone Health \/ NIDA"}]

    Find Clinical Drug Pipeline Developments & Deals by NYU Langone Health

    Menu

    NYU Langone Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : NIDA

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            $15M NIDA Grant Funds Psilocybin Study in Opioid Use Disorder

                            Details : The funding will support the first clinical trial to evaluate psilocybin's efficacy as a treatment for Opioid Use Disorder (OUD).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : NIDA

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety...

                            Details : Nantheia ATL5, an oral therapy containing 100mg of cannabidiol per capsule, features proprietary delivery technology (Liquid Structure) touted as enhancing the effectiveness and stability of cannabidiol.

                            Brand Name : Nantheia

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : Orcosa

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX

                            Details : On the first day after surgery, patients receiving ORAVEXX (cannabidiol, CBD), experienced on average 23% less pain as measured by the Visual Analog Scale (VAS) pain score compared to patients receiving the placebo.

                            Brand Name : Oravexx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Orcosa

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth